Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 7/20 | 0.68 |
| ▸ | PGR | P06401 | 4/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | IL1RN | P18510 | 1/20 | 0.59 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.59 |
| ▸ | IKBKB | O14920 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14425657 | 0.90 | HTR6 (0.72) | HTR6PGRPOLBIL1RNKEAP1 | |
| SCHEMBL1696862 | 0.84 | HTR6 (0.68) | HTR6PGRPOLBIL1RNKEAP1 | |
| SCHEMBL23306394 | 0.84 | HTR6 (0.68) | HTR6PGRPOLBIL1RNKEAP1 | |
| SCHEMBL8081768 | 0.82 | KEAP1 (0.79) | HTR6PGRPOLBIL1RNKEAP1 | |
| SCHEMBL2889311 | 0.82 | IKBKB (0.67) | HTR6POLBIKBKBHDAC2HDAC8 | |
| SCHEMBL28182427 | 0.82 | HTR6 (0.62) | HTR6PGRPOLBIL1RNKEAP1 | |
| SCHEMBL10453153 | 0.81 | KMT2A (0.67) | HTR6IL1RNKEAP1ERAP1IKBKB | |
| SCHEMBL2822371 | 0.81 | MEN1 (0.67) | HTR6PGRIL1RNKEAP1ERAP1 | |
| SCHEMBL4061585 | 0.81 | KEAP1 (0.69) | POLBKEAP1HDAC2HDAC8HDAC6 | |
| SCHEMBL14015271 | 0.80 | HTR6 (0.63) | HTR6PGRPOLBIL1RNKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557140-B2 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2009-07-07 | — | — | US | disclosed |
| EP-1317443-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2009-01-14 | — | — | EP | disclosed |
| US-7407988-B2 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2008-08-05 | — | — | US | disclosed |
| US-20080161401-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2008-07-03 | — | — | US | disclosed |
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | GENZYME CORPORATION | 2008-04-17 | — | — | US | disclosed |
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | GENZYME CORPORATION | 2008-04-17 | — | — | US | disclosed |
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | GENZYME CORPORATION | 2008-04-17 | — | — | US | disclosed |
| US-7312234-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2007-12-25 | — | — | US | disclosed |
| US-7312234-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2007-12-25 | — | — | US | disclosed |
| US-7312234-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2007-12-25 | — | — | US | disclosed |
| US-7183298-B2 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2007-02-27 | — | — | US | disclosed |
| US-20070004806-A1 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2007-01-04 | — | — | US | disclosed |
| US-20050026942-A1 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2005-02-03 | — | — | US | disclosed |
| US-6835731-B2 | Viricides; antiinflammatory agents; antiallergens; antiarthritic agents | ANORMED, INC. (CA) | 2004-12-28 | — | — | US | disclosed |
| EP-1317443-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2003-06-11 | — | — | EP | disclosed |
| US-20020147192-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2002-10-10 | — | — | US | disclosed |
| WO-2002022599-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147192-A1 | Chemokine receptor binding heterocyclic compounds | CCR2, CXCR3, ACKR3 | HTR6 637/4885PGR 812/4885POLB 1920/4885 |
| US-20070004806-A1 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | HDAC1, HDAC11, HDAC3 | HTR6 3341/4885PGR 1115/4885POLB 3558/4885 |
| US-20080161401-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS | HDAC1, HDAC11, HDAC3 | HTR6 3341/4885PGR 1115/4885POLB 3558/4885 |
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | CCR2, CXCR3, ACKR3 | HTR6 637/4885PGR 812/4885POLB 1920/4885 |
| US-20050026942-A1 | Chemokine receptor binding heterocyclic compounds | CCR2, CXCR3, ACKR3 | HTR6 637/4885PGR 812/4885POLB 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.